Bernard J Park1, Hao-Xian Yang1, Kaitlin M Woo1, Camelia S Sima1. 1. 1 Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA ; 2 Weill Cornell Medical College, New York, NY, USA ; 3 Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China ; 4 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: Insufficient data exist on the results of minimally invasive surgery (MIS) for locally advanced non-small cell lung cancer (NSCLC) traditionally approached by thoracotomy. The use of telerobotic surgical systems may allow for greater utilization of MIS approaches to locally advanced disease. We will review the existing literature on MIS for locally advanced disease and briefly report on the results of a recent study conducted at our institution. METHODS: We performed a retrospective review of a prospective single institution database to identify patients with clinical stage II and IIIA NSCLC who underwent lobectomy following induction chemotherapy. The patients were classified into two groups (MIS and thoracotomy) and were compared for differences in outcomes and survival. RESULTS: From January 2002 to December 2013, 428 patients {397 thoracotomy, 31 MIS [17 robotic and 14 video-assisted thoracic surgery (VATS)]} underwent induction chemotherapy followed by lobectomy. The conversion rate in the MIS group was 26% (8/31) The R0 resection rate was similar between the groups (97% for MIS vs. 94% for thoracotomy; P=0.71), as was postoperative morbidity (32% for MIS vs. 33% for thoracotomy; P=0.99). The median length of hospital stay was shorter in the MIS group (4 vs. 5 days; P<0.001). The 3-year overall survival (OS) was 48.3% in the MIS group and 56.6% in the thoracotomy group (P=0.84); the corresponding 3-year DFS were 49.0% and 42.1% (P=0.19). CONCLUSIONS: In appropriately selected patients with NSCLC, MIS approaches to lobectomy following induction therapy are feasible and associated with similar disease-free and OS to those following thoracotomy.
BACKGROUND: Insufficient data exist on the results of minimally invasive surgery (MIS) for locally advanced non-small cell lung cancer (NSCLC) traditionally approached by thoracotomy. The use of telerobotic surgical systems may allow for greater utilization of MIS approaches to locally advanced disease. We will review the existing literature on MIS for locally advanced disease and briefly report on the results of a recent study conducted at our institution. METHODS: We performed a retrospective review of a prospective single institution database to identify patients with clinical stage II and IIIA NSCLC who underwent lobectomy following induction chemotherapy. The patients were classified into two groups (MIS and thoracotomy) and were compared for differences in outcomes and survival. RESULTS: From January 2002 to December 2013, 428 patients {397 thoracotomy, 31 MIS [17 robotic and 14 video-assisted thoracic surgery (VATS)]} underwent induction chemotherapy followed by lobectomy. The conversion rate in the MIS group was 26% (8/31) The R0 resection rate was similar between the groups (97% for MIS vs. 94% for thoracotomy; P=0.71), as was postoperative morbidity (32% for MIS vs. 33% for thoracotomy; P=0.99). The median length of hospital stay was shorter in the MIS group (4 vs. 5 days; P<0.001). The 3-year overall survival (OS) was 48.3% in the MIS group and 56.6% in the thoracotomy group (P=0.84); the corresponding 3-year DFS were 49.0% and 42.1% (P=0.19). CONCLUSIONS: In appropriately selected patients with NSCLC, MIS approaches to lobectomy following induction therapy are feasible and associated with similar disease-free and OS to those following thoracotomy.
Entities:
Keywords:
Lobectomy; lung cancer surgery; minimally invasive surgery (MIS); thoracotomy
Authors: Subroto Paul; Nasser K Altorki; Shubin Sheng; Paul C Lee; David H Harpole; Mark W Onaitis; Brendon M Stiles; Jeffrey L Port; Thomas A D'Amico Journal: J Thorac Cardiovasc Surg Date: 2010-02 Impact factor: 5.209
Authors: Subroto Paul; Art Sedrakyan; Ya-Lin Chiu; Abu Nasar; Jeffrey L Port; Paul C Lee; Brendon M Stiles; Nasser K Altorki Journal: Eur J Cardiothorac Surg Date: 2012-07-22 Impact factor: 4.191
Authors: Franca M A Melfi; Olivia Fanucchi; Federico Davini; Gaetano Romano; Marco Lucchi; Paolo Dini; Marcello C Ambrogi; Alfredo Mussi Journal: Eur J Cardiothorac Surg Date: 2014-03-09 Impact factor: 4.191
Authors: Giorgio V Scagliotti; Ugo Pastorino; Johan F Vansteenkiste; Lorenzo Spaggiari; Francesco Facciolo; Tadeusz M Orlowski; Luigi Maiorino; Martin Hetzel; Monika Leschinger; Carla Visseren-Grul; Valter Torri Journal: J Clin Oncol Date: 2011-11-28 Impact factor: 44.544
Authors: Scott J Swanson; Daniel L Miller; Robert Joseph McKenna; John Howington; M Blair Marshall; Andrew C Yoo; Matthew Moore; Candace L Gunnarsson; Bryan F Meyers Journal: J Thorac Cardiovasc Surg Date: 2013-11-08 Impact factor: 5.209
Authors: R Arriagada; A Auperin; S Burdett; J P Higgins; D H Johnson; T Le Chevalier; C Le Pechoux; M K B Parmar; J P Pignon; R L Souhami; R J Stephens; L A Stewart; J F Tierney; H Tribodet; J van Meerbeeck Journal: Lancet Date: 2010-03-24 Impact factor: 79.321
Authors: Masha Zeltsman; Jordan Dozier; Raj G Vaghjiani; Alexandra Poch; Takashi Eguchi; Alessia Pedoto; David R Jones; Prasad S Adusumilli Journal: Lung Cancer Date: 2019-11-11 Impact factor: 5.705